The UK Pharmacogenetics & Stratified Medicine Network Open Meeting took place on March 21, 2018 at 30 Euston Square, London.
Upwards of 200 delegates were treated to a fascinating range of talks from leading figures in the field as well as personal accounts from patients.
During the first session, Professor Sir Munir Pirmohamed discussed the success of his Genotype-Guided Warfarin Dosing pilot, as well as the NHS genomic medicine goals for 2020 and 2025.
Sir John Savill outlined the MRC's consortium approach, referring to 95 industry/academia partnerships.
Doctor Karen Spink announced some exciting new initiatives and funding competitions from Innovate UK, including the new Precision Medicine Investor Accelerator, also revealing that every £1 spent by Innovate UK has led to £7.30 in investment.
NIHR CRN Cluster Lead Professor Michael Beresford described how services are being improved to better deliver stratified medicine research.
The second session featured a number of disease-specific talks, outlining how stratified medicine is working in asthma, psoriasis and primary biliary cholangitis.
Janette Rawlinson discussed the stigma attached to lung cancer, something that as a never-smoked lung cancer patient she has experienced firsthand.
During the afternoon, we heard from Professor Magnus Ingelman-Sundberg on implementing WGS analyses into pre-emptive pharmacogenomics advice and Professor Sir Munir Pirmohamed was back to discuss the pharmacogenomics of serious adverse drug reactions.
Stuart Doyle provided an unforgettable account of his personal journey through SJS and TENS; his inspirational and grateful comments addressed to those who spend hours, days and weeks working on spreadsheets of data had a marked effect on the audience.
The final session highlighted some of the exciting progress and bold upcoming projects from the industry sector.
Delegate feedback is currently being gathered, the results of this will be published here shortly. All the talks at the event were recorded and will be available to view in due course.
The 6th Annual Open Meeting will take place on March 20, 2019.